The approaching mega-IPO cycle will function as a transient liquidity absorber across risk assets before post-lockup wealth ...
The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech ...
SpaceX’s potential $1.75T IPO could reshape markets. Learn how investors can gain exposure through XOVR ETF and why structure matters for returns and liquidity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results